Phase I trial of weekly gemcitabine with radiotherapy for unresectable locally advanced biliary tract cancer.

Phase I trial of weekly gemcitabine with radiotherapy for unresectable locally advanced biliary tract cancer. - Phase I trial of weekly gemcitabine with radiotherapy for unresectable locally advanced biliary tract cancer.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022562

Enrollment

Registered

2016-06-01

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Interventions

Chemoradiotherapy (with gemcitabine) Radiotherapy : total 50.4Gy/28Fr. Once a day ( 1.8Gy/day), five times a week. Gemcitabine : div day1,8,15,22,29,36 Increase the dose of gemcitabine : 400mg/m2,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable locally advanced biliary tract cancer

Exclusion criteria

Exclusion criteria: No previous history of treatment.

Design outcomes

Primary

Measure	Time frame
Adverse events within two weeks after treatment.	—

Secondary

Measure	Time frame
Maximum tolerated dose, toxicity	—

Countries

Japan

Contacts

Public ContactMichihiro Ono

Sapporo medical university department of medical oncology

onomichihiro34@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026